Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 10;14(2):411.
doi: 10.3390/jcm14020411.

Peripheral Extracellular Vesicles for Diagnosis and Prognosis of Resectable Lung Cancer: The LUCEx Study Protocol

Jorge Rodríguez-Sanz  1   2   3 , Nadia Muñoz-González  2   3   4 , José Pablo Cubero  2   3 , Pablo Ordoñez  4 , Victoria Gil  2   3 , Raquel Langarita  2   3 , Myriam Ruiz  2   3 , Marta Forner  2   3 , Marta Marín-Oto  2   3 , Elisabet Vera  1 , Pedro Baptista  5 , Francesca Polverino  6 , Juan Antonio Domingo  1 , Javier García-Tirado  4 , José María Marin  1   2   3 , David Sanz-Rubio  2   3
Affiliations

Peripheral Extracellular Vesicles for Diagnosis and Prognosis of Resectable Lung Cancer: The LUCEx Study Protocol

Jorge Rodríguez-Sanz et al. J Clin Med. .

Abstract

Background/Objectives: Lung cancer is the primary cause of cancer-related deaths. Most patients are typically diagnosed at advanced stages. Low-dose computed tomography (LDCT) has been proven to reduce lung cancer mortality, but screening programs using LDCT are associated with a high number of false positives and unnecessary thoracotomies. It is therefore imperative that a certain diagnosis is refined, especially in cases of solitary pulmonary nodules that are difficult to technically access for an accurate preoperative diagnosis. Extracellular vesicles (EVs) involved in intercellular communication may be an innovative biomarker for diagnosis and therapeutic strategies in lung cancer, regarding their ability to carry tumor-specific cargo. The aim of the LUCEx study is to determine if extracellular vesicle cargoes from both lung tissue and blood could provide complementary information to screen lung cancer patients and enable personalized follow-up after the surgery. Methods: The LUCEx study is a prospective study aiming to recruit 600 patients with lung cancer and 50 control subjects (false positives) undergoing surgery after diagnostic imaging for suspected pulmonary nodules using computed tomography (CT) scans. These patients will undergo curative surgery at the Department of Thoracic Surgery of the Miguel Servet Hospital in Zaragoza, Spain, and will be followed-up for at least 5 years. At baseline, samples from both tumor distal lung tissue and preoperative peripheral blood will be collected and processed to compare the quantity and content of EVs, particularly their micro-RNA (miRNA) cargo. At the third and fifth years of follow-up, CT scans, functional respiratory tests, and blood extractions will be performed. Discussion: Extracellular vesicles and their miRNA have emerged as promising tools for the diagnosis and prognosis of several diseases, including cancer. The LUCEx study, based on an observational clinical cohort, aims to understand the role of these vesicles and their translational potential as complementary tools for imaging diagnosis and prognosis.

Keywords: diagnosis; exosomes; extracellular vesicle; lung cancer; micro-RNA; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Exosome isolation process in solid tissue (created in BioRender.com).
Figure 2
Figure 2
Exosome isolation process in blood plasma (created in BioRender.com).
Figure 3
Figure 3
Planned flowchart for the sample size described.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024;74:229–263. doi: 10.3322/caac.21834. - DOI - PubMed
    1. Ost D.E., Yeung S.C.J., Tanoue L.T., Gould M.K. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143:121–141. doi: 10.1378/chest.12-2352. - DOI - PMC - PubMed
    1. Nasim F., Sabath B.F., Eapen G.A. Lung Cancer. Med. Clin. N. Am. 2019;103:463–473. doi: 10.1016/j.mcna.2018.12.006. - DOI - PubMed
    1. Bade B.C., Cruz C.S.D. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin. Chest Med. 2020;41:1–24. doi: 10.1016/j.ccm.2019.10.001. - DOI - PubMed
    1. Cui S., Cheng Z., Qin W., Jiang L. Exosomes as a liquid biopsy for lung cancer. Lung Cancer. 2018;116:46–54. doi: 10.1016/j.lungcan.2017.12.012. - DOI - PubMed

LinkOut - more resources